On the contrary, PD-1/PD-L1 inhibitors effectively block the PD-1/PD-L1 pathway and enhance the activity of T cell, thus achieving the effect of tumor immunotherapy [13,14,15] (see Figure 1 in detail). The gene discussed is CD274; the disease is neoplasm.